Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 10/20 | 0.65 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852296 | 0.94 | GPR52 (0.59) | GPR52S1PR4S1PR5MRGPRX4HDAC4 | |
| SCHEMBL3222989 | 0.92 | GPR52 (0.76) | GPR52S1PR4S1PR5MRGPRX4 | |
| SCHEMBL1852957 | 0.90 | GPR52 (0.64) | GPR52S1PR4S1PR5MRGPRX4MAPT | |
| SCHEMBL3223155 | 0.87 | GPR52 (0.63) | GPR52S1PR4S1PR5MRGPRX4IGF1R | |
| SCHEMBL3219557 | 0.87 | GPR52 (0.61) | GPR52MRGPRX4MAPT | |
| SCHEMBL3212807 | 0.85 | GPR52 (0.74) | GPR52S1PR4S1PR5MRGPRX4 | |
| SCHEMBL3217505 | 0.84 | MAOB (0.52) | GPR52S1PR4S1PR5MRGPRX4IGF1R | |
| SCHEMBL1858166 | 0.83 | GPR52 (0.56) | GPR52S1PR4S1PR5MRGPRX4IGF1R | |
| SCHEMBL3213544 | 0.83 | GPR52 (0.46) | GPR52S1PR4S1PR5MRGPRX4IGF1R | |
| SCHEMBL3209960 | 0.80 | GPR52 (0.64) | GPR52S1PR4S1PR5MRGPRX4HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885S1PR4 565/4885S1PR5 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.